Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 5/20 | 0.39 |
| ▸ | SQLE | Q14534 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5866150 | 0.84 | F2 (0.51) | F2 | |
| SCHEMBL5866154 | 0.84 | F2 (0.38) | PPARAF2PPARGCA12CA1 | |
| SCHEMBL5866135 | 0.78 | NR3C1 (0.46) | NR3C1PGRF2POLBMAPT | |
| SCHEMBL5866390 | 0.78 | KEAP1 (0.53) | NR3C1PGRPOLBFFAR1 | |
| SCHEMBL5866178 | 0.73 | F2 (0.36) | F2 | |
| SCHEMBL5866176 | 0.72 | F2 (0.36) | F2 | |
| SCHEMBL5866185 | 0.71 | AR (0.56) | PGRF2 | |
| SCHEMBL5866307 | 0.71 | KEAP1 (0.43) | PPARDPPARANR3C1PGRPPARG | |
| SCHEMBL7425998 | 0.71 | MAOB (0.58) | PPARDPPARACA12CA1CA2 | |
| SCHEMBL5866160 | 0.67 | F2 (0.55) | PPARDPPARAF2MAPTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074820-B2 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| EP-0917528-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| US-20020040043-A1 | Amidino derivatives and their use as thrombin inhibitors | ANTONSSON THOMAS (SE) | 2002-04-04 | — | — | US | disclosed |
| US-6221898-B1 | ANTICOAGULANTS | ASTRA AKTIEBOLAG (SE) | 2001-04-24 | — | — | US | disclosed |
| EP-0917528-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-05-26 | — | — | EP | disclosed |
| WO-1998001422-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040043-A1 | Amidino derivatives and their use as thrombin inhibitors | SERPINC1, F2, SERPINE1 | PPARD 2698/4885PPARA 3313/4885NR3C1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.